Cost-effectiveness analysis of elranatamab versus physician's choice of treatment (non-BCMA-directed regimens) in patients with triple class exposed multiple myeloma in Japan.

Akira Yuasa¹, Mitsuhiro Nagano¹, Yoichi Kamei², Kengo Hatsuyama³, Hiroyuki Matsuda³, Patrick Hlavacek⁴, Marco DiBonaventura⁴, Kenshi Suzuki⁵

¹Japan Access & Value, Pfizer Japan Inc, Tokyo, Japan.

²Pfizer R&D Japan G.K, Tokyo, Japan.

³Real World Evidence Solutions & HEOR, IQVIA Solutions Japan G.K, Tokyo, Japan.

⁴HTA, Value & Evidence, Pfizer Inc, New York, NY, USA.

⁵Myeloma/AL Amyloid Unit, Japanese Red Cross Medical Center, Tokyo, Japan.

PubMed DOI

Abstract

AIM: To evaluate the cost-effectiveness of elranatamab versus physician's choice of treatment (PCT) for patients with triple class exposed multiple myeloma in Japan. MATERIALS AND METHODS: A cost-effectiveness analysis was conducted comparing elranatamab with PCT using a partitioned survival model with three health states from the Japanese public healthcare payer perspective. A weekly cycle lengt…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.